NL-OMON22563已完成不适用
Dosefinding trial studying effect of 4 weeks Intervention on safety and efficacy in males with Metabolic syndrome with oral Eubacterium hallii
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AMC
- 入组人数
- 27
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Caucasian obese subjects with metabolic syndrome (males, aged 21 to 69 years-old; body mass index (BMI) 25 to 43 kg/m2, fasting plasma glucose > 5.6 mmol/l, fasting triglycerides > 1.7 mmol/l, waist circumference > 102 cm)
- •- No concomitant medication
排除标准
- •- History of cardiovascular event (myocardial infarction or pacemaker implantation)
- •- Cholecystectomy
研究者
相似试验
已完成
2 期
Dosefinding trial studying effect of 4 weeks Intervention on safety and efficacy in males with Metabolic syndrome treated with oral Eubacterium halliiMetabolic syndrome10018424NL-OMON44478Academisch Medisch Centrum27
已完成
不适用
4-Week Study of 'MYP/MYPlus' Natural Extract for Improving COVID-19 Related FatigueSymptoms, signs and abnormal clinical and laboratory findings, NECKCT0008948Daejeon Korean Medicine Hospital of Daejeon University100
已完成
不适用
Clinical trial to evaluate the influence of 6 day-dexamethasone (inducer of CES1)Diseases of th respiratory systemKCT0001533Bundang CHA General Hospital20
进行中（未招募）
不适用
A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects with COPD.Chronic Obstructive Pulmonary DiseaseEUCTR2010-022796-62-SEGlaxoSmithKline Research & Development Ltd425
进行中（未招募）
不适用
A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects with COPD.Chronic Obstructive Pulmonary DiseaseEUCTR2010-022796-62-SKGlaxoSmithKline Research & Development Ltd425